To evaluate the effect of dietary chromium supplements on glucose and insulin response in healthy people and in people with glucose intolerance or type 2 diabetes.
Two reviewers independently extracted the data using specially designed forms and resolved any disagreements with the aid of a third reviewer. Data were extracted on study design, number randomised and number analysed, study population, country, chromium dose and formulation, control treatment, maximum follow-up and outcomes. The authors of the primary studies were contacted for missing details. For crossover RCTs, only data from the first period were used. For each study the difference in the means and 95% confidence intervals (CIs) were calculated for glucose, insulin and HbA1c concentrations. For studies with more than one chromium or placebo treatment arm and similar groups, an average response was calculated, weighted by sample size. Groups that were not similar were treated as separate treatments.
Methods of synthesis
How were the studies combined? The pooled mean differences and 95% CIs between chromium and control (placebo or active) were calculated for diabetic and nondiabetic patients using two different fixed-effect models (weighted mean differences and standardised mean differences). The intention was only to report the weighted mean difference unless results from the models were dissimilar. The nondiabetic population included healthy people and glucose intolerant people. One study was subsequently excluded from the formal meta-analysis because it was the only study conducted in a non-Western country and its inclusion in the meta-analysis led to significant heterogeneity. Studies of diabetics appear to have been combined in a narrative that included the RCT excluded from the meta-analysis.
How were differences between studies investigated?
Statistical heterogeneity was tested using the chi-squared test, taking a P-value of less than 0.05 to indicate significant heterogeneity. Where heterogeneity was explained by one or two studies, these studies were removed from the metaanalysis. Where heterogeneity could not be explained by one or two studies, a random-effects model was used to combine the data. Linear regression was used to assess the influence of chromium formulation, chromium dose and exercise level on the relationship between dietary chromium and glycaemic control.
Results of the review
Information on 20 studies was tabulated, but only 15 RCTs with sufficient data were included in the review (618 people: 193 with type 2 diabetes and 425 who were either in good health or had glucose impairment).
Eleven RCTs analysed data from 90% or more of the patients randomised. Overall, 15% of the randomised patients were lost to follow-up or excluded from analyses. Only 4 RCTs reported baseline chromium levels.
Fasting glucose (14 RCTs; 38 diabetic and 425 nondiabetic patients).
Overall, there was no statistically-significant difference in fasting glucose between chromium supplements and control; the mean difference was 0.027 mmol/L (95% CI: -0.09, 0.15). No significant heterogeneity was found (P=0.97). There was also no statistically-significant difference in fasting glucose between chromium supplements and control among nondiabetics; the mean difference was 0.028 mmol/L (95% CI: -0.086, 0.14). The results for diabetics (4 RCTs) were inconclusive. Three small RCTs found no significant difference between chromium and control. The fourth RCT (180 randomised, 155 analysed) found that 1,000 microg chromium significantly decreased fasting glucose compared with placebo; the mean difference was -1.70 mmol/L (95% CI: -2.41, -0.99). However, it found no significant difference with 200 microg chromium; the mean difference was -1.0 mmol/L (95% CI: -0.93, 0.73). This RCT was the only one conducted in a non-Western country.
Glucose at 120 minutes (5 RCTs; 8 diabetics and 133 nondiabetics).
Overall, there was no statistically-significant difference in glucose at 120 minutes between chromium supplements and control; the mean difference was 0.26 mmol/L (95% CI: -0.24, 0.76). No significant heterogeneity was found (P=0.98). There was also no statistically-significant difference in fasting glucose between chromium supplements and control among nondiabetics,; the mean difference was 0.042 mmol/L (95% CI: -0.43, 0.52). Among diabetics (4 RCTs), one RCT found that 1,000 microg chromium significantly decreased glucose compared with placebo, but it found no significant difference with 200 microg chromium. One small RCT found no significant difference between the treatments.
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Fasting insulin (10 RCTs).
Overall, there was no statistically-significant difference in fasting insulin between chromium supplements and control; the mean difference was 0.28 mmol/L (95% CI: -7.0, 7.5). No significant heterogeneity was found (P=0.097). There was also no statistically-significant difference in fasting insulin between chromium supplements and control among nondiabetics; the mean difference was 0.25 mmol/L (95% CI: -6.98, 7.48). The results for diabetics (2 RCTs) were mixed with one study (8 patients) finding no significant difference and the other larger study (155 patients) finding that chromium significantly reduced fasting insulin compared with placebo.
Insulin at 120 minutes (5 RCTs; 8 diabetics and 133 nondiabetics).
There was no statistically-significant difference in insulin between chromium supplements and control, both overall and in nondiabetics. The mean difference overall was 11.1 pmol/L (95% CI: -69.0, 91.2); no significant heterogeneity was found (P=0.15). The mean difference for nondiabetics was 5.5 pmol/L (95% CI: -74.0, 85.1). Among diabetics (2 RCTs), one RCT (non Western population) found that chromium (1,000 and 200 microg) significantly reduced insulin at 120 minutes compared with placebo; the mean differences were -63 picomol/L (95% CI: -79.6, -46.4) and -63 picomol/L (95% CI: -78.3, -47.7) for doses of 1,000 and 200 microg chromium, respectively. A second small RCT found no significant difference.
HbA1c (3 RCTs).
One RCT of 33 healthy patients found no significant difference between chromium and control, as did another RCT of 24 patients with glucose intolerance. One RCT (155 diabetics) found that chromium (1,000 and 200 microg) significantly reduced HbA1c in comparison with placebo with a dose-relationship response; the mean differences were -1.90% (95% CI: -2.34, -1.46) and -1.00% (95% CI: -1.55, -0.45) for doses of 1,000 and 200 microg chromium, respectively.
Chromium formulation, chromium dose and exercise level did not influence the effect of chromium on fasting glucose or insulin.
None of the RCTs reported any adverse events with chromium supplements.
